Showing results (121-130 of 160) with videos related to

Sort By:
Pageof 16
Genome Medicine|February 24, 2020
Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancerQing Zhou, Samantha O Perakis, Peter Ulz, et al.
Plos One|April 22, 2017
Risk stratification for venous thromboembolism in patients with testicular germ cell tumorsAngelika Bezan, Florian Posch, Ferdinand Ploner, et al.
Oncotarget|April 11, 2015
Low spinophilin expression enhances aggressive biological behavior of breast cancerDaniela Schwarzenbacher, Verena Stiegelbauer, Alexander Deutsch, et al.
Annals of Surgical Oncology|September 13, 2017
Benefit of Adjuvant Radiotherapy for Local Control, Distant Metastasis, and Survival Outcomes in Patients with Localized Soft Tissue Sarcoma: Comparative Effectiveness Analysis of an Observational Cohort StudyFlorian Posch, Richard Partl, Carmen Döller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancerArmin Gerger, Anthony El-Khoueiry, Wu Zhang, et al.
Plos One|November 10, 2017
SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer typesGeorg Richtig, Ariane Aigelsreiter, Daniela Schwarzenbacher, et al.
ESMO Open|September 24, 2020
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancerSamantha O Perakis, Sabrina Weber, Qing Zhou, et al.
Scientific Reports|April 5, 2019
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysisFlorian Moik, Jakob M Riedl, Thomas Winder, et al.
Therapeutic Advances in Medical Oncology|March 15, 2021
Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trialJakob M Riedl, Samantha O Hasenleithner, Gudrun Pregartner, et al.
Molecular Cancer Therapeutics|March 7, 2012
The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer modelsYan Ning, Melissa J Labonte, Wu Zhang, et al.
Pageof 16